REGULATORY SCRUTINY IN PHARMA

Healthcare investors go for full-body check-up: Forensic due diligence rise as sector faces scrutiny

“There has been a rise in forensic due diligence given higher scrutiny surrounding the pharma and healthcare segment. “Over the last year, it has also witnessed a surge in deal-making activity so much that PEs and VCs are demanding to delve deeper in terms of investigating beyond the regular accounting”, said Amit Rahane, partner, Forensic & Integrity Services at EY.